Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets open weak
Mon, 24 Jun 09:30 am

All the major Asian stock markets have opened the day in the red with Hong Kong (down 1.6 %) and China (down 3.0%) leading the pack of losers. The Indian share markets indices have also opened the day on a negative note. Barring healthcare, all other sectoral indices have opened in the red with the stocks in the power and consumer durables space leading the losses.

The Sensex today is down by around 106 points (0.6%), while the NSE-Nifty is down by around 35 points (0.6%). Mid cap and small cap stocks have also opened in the red with BSE Mid Cap index and BSE Small Cap down by around 0.8% and 0.5% respectively. The rupee is trading at Rs 59.67 to the US dollar.

Indian Pharma stocks have opened the day on a mixed note with Glenmark Pharma Ltd and Orchid Chemicals Ltd leading the gains. However, Panacea Biotech and Piramal Enterprises were witnessing selling pressure. As per a leading financial daily, Ranbaxy Ltd's third and newly commissioned Mohali facility has come under the scanner of US Food and Drug Administration (USFDA). The latter has issued Form 483 to the company's manufacturing facility at Mohali a few months ago post finding deviations from its norms during an inspection of the plant. It is important to note here that Form 483 is issued by the FDA at the conclusion of an inspection to notify the company of objectionable conditions that might be in violation of the US Food, Drug and Cosmetic Act and related laws. However, it does not prevent a company from making regulatory filings from that unit. This is a negative development for the company as the Mohali unit forms an important part of Ranbaxy's strategy.

Telecom stocks have opened on a mixed note with Idea Cellular Ltd and Himachal Futuristic leading the gains. However, Tata Teleservices and AGC Networks Ltd are leading the losses. As per a leading financial daily, Bharti Airtel will slash 4G data charges by 31% from today. The move aims to boost demand for fourth-generation wireless broadband services. It is important to note here that Mukesh Ambani's Reliance Jio Infocomm is slated to roll out 4G services on a pan-India basis within this year. It is also likely to make things difficult for future challengers. As per the daily, Airtel will offer 4G speeds at 3G price points. Earlier, the company had cut 2G data charges by nearly 90% to boost data usage and revenue streams.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open weak". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.